IRIS  Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise

LUBRANO DI SCORPANIELLO, Ennio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.057
EU - Europa 11.054
AS - Asia 4.388
SA - Sud America 1.221
AF - Africa 554
Continente sconosciuto - Info sul continente non disponibili 503
OC - Oceania 28
Totale 32.805
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.755
RU - Federazione Russa 4.924
IE - Irlanda 1.964
SG - Singapore 1.963
BR - Brasile 930
CN - Cina 882
IT - Italia 727
FR - Francia 584
UA - Ucraina 548
DE - Germania 478
FI - Finlandia 460
AT - Austria 374
CI - Costa d'Avorio 357
VN - Vietnam 340
SE - Svezia 333
GB - Regno Unito 325
BD - Bangladesh 216
HK - Hong Kong 216
IN - India 192
CA - Canada 151
AR - Argentina 95
MX - Messico 78
IQ - Iraq 70
JP - Giappone 69
TR - Turchia 68
ZA - Sudafrica 65
NL - Olanda 61
PL - Polonia 60
CO - Colombia 46
ES - Italia 46
EC - Ecuador 45
BE - Belgio 42
ID - Indonesia 42
PK - Pakistan 42
VE - Venezuela 38
SA - Arabia Saudita 33
LT - Lituania 27
MA - Marocco 26
AU - Australia 22
PH - Filippine 22
AZ - Azerbaigian 20
CL - Cile 20
MY - Malesia 20
UZ - Uzbekistan 20
IR - Iran 19
IL - Israele 18
TN - Tunisia 18
EG - Egitto 17
KR - Corea 17
KZ - Kazakistan 16
JO - Giordania 15
BO - Bolivia 14
EU - Europa 14
JM - Giamaica 14
DZ - Algeria 13
PE - Perù 13
RO - Romania 13
AE - Emirati Arabi Uniti 12
KE - Kenya 12
NP - Nepal 11
CZ - Repubblica Ceca 10
HR - Croazia 10
PY - Paraguay 10
UY - Uruguay 10
CH - Svizzera 9
PA - Panama 9
PT - Portogallo 9
TT - Trinidad e Tobago 9
KG - Kirghizistan 8
OM - Oman 8
SC - Seychelles 8
TH - Thailandia 8
AL - Albania 7
CR - Costa Rica 7
ET - Etiopia 7
SN - Senegal 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
GE - Georgia 6
GR - Grecia 6
GT - Guatemala 6
NI - Nicaragua 6
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
AO - Angola 4
DK - Danimarca 4
HN - Honduras 4
KW - Kuwait 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
BY - Bielorussia 3
CY - Cipro 3
HU - Ungheria 3
NO - Norvegia 3
XK - ???statistics.table.value.countryCode.XK??? 3
GI - Gibilterra 2
KN - Saint Kitts e Nevis 2
Totale 32.272
Salva come PNG Salva come JPEG
Città #
Dallas 4.387
Dublin 1.963
Moscow 1.655
San Jose 1.507
Jacksonville 1.323
Chandler 1.133
Singapore 1.037
Ashburn 618
The Dalles 434
Wilmington 409
Vienna 366
Abidjan 357
Helsinki 316
Rome 299
Houston 266
Beijing 259
San Mateo 248
Lauterbourg 227
Hong Kong 209
Ann Arbor 185
Los Angeles 183
Princeton 179
Boardman 148
Woodbridge 146
Santa Clara 144
New York 137
Ho Chi Minh City 123
Frankfurt am Main 113
Columbus 106
Council Bluffs 100
Dearborn 94
São Paulo 88
Tokyo 63
Orem 62
Hanoi 61
Milan 53
Warsaw 48
Chicago 47
Toronto 46
Brooklyn 44
Amsterdam 43
Redwood City 41
London 39
San Francisco 39
Chennai 38
Montreal 38
Rio de Janeiro 38
Denver 37
Johannesburg 37
Mountain View 36
Brussels 35
Atlanta 34
Molise 34
Mexico City 32
Hillsboro 29
Manchester 28
Jinan 27
Dhaka 26
Nuremberg 25
Baghdad 24
Seattle 22
Boston 20
Shanghai 20
Baku 19
Nanjing 19
Lahore 18
Shenyang 18
Tashkent 18
Falls Church 17
Guangzhou 17
Istanbul 17
Mumbai 17
Ottawa 17
Phoenix 17
Caracas 16
Naples 15
Amman 14
Augusta 14
Las Vegas 14
Ningbo 14
Stockholm 14
Auburn Hills 13
Buffalo 13
Jakarta 13
Leawood 13
Porto Alegre 13
Quito 13
Belo Horizonte 12
Bogotá 12
Curitiba 12
Fortaleza 12
Haikou 12
Paris 12
Poplar 12
Brasília 11
Campinas 11
Charlotte 11
Falkenstein 11
Guayaquil 11
Haiphong 11
Totale 20.448
Salva come PNG Salva come JPEG
Nome #
A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action 2.733
An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment 249
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 235
Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors 219
An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings 217
Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting 210
An overview of low disease activity and remission in psoriatic arthritis. 207
An audit of anthropometric measurements by medical and physiotherapy staff in patients with ankylosing spondylitis 206
ANTHROPOMETRIC MEASUREMENTS AND DISABILITY IN A OPEN FOLLOW UP STUDY ON ANKYLOSING SPONDYLITIS WITH COMBINED MEDICAL AND REHABILITATIVE TREATMENT 198
Assessment of bone morphogenic protein 2 and interleukine-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study 190
Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report 187
Assessment of subclinical atherosclerosis in ankylosing spondylitis: Correlations with disease activity indices 185
Aortic involvement in ankylosing spondylitis 184
Antiphospholipid syndrome, activated protein C resistance and mutation C -> T 677 in the MTHFR gene with juvenile pulmonary embolism. A case report 184
Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis 183
A novel biological target for the treatment of psoriatic arthritis. 183
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis 183
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients 183
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: Association with disease activity and quality of life indices 178
From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications 177
A rare enthesopathy in psoriatic oligoarthritis 175
La spondilodiscite delle spondiloartriti sieronegative 171
A national survey on the management of psoriatic arthritis using the Delphi method 171
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 170
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. 169
Measuring psoriatic disease in clinical practice. An expert opinion position paper. 168
Assessment of psoriatic nail disease activity by rheumatologists 166
Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis 165
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study 164
The arthritis of coeliac disease: prevalence and pattern in 200 adult patients 160
Iperuricemia e rischio cardio-renale 160
Venous thrombophilia in a patient with protein S deficiency, factor V Leiden and homozygous MTHFR C -> T677 mutation 157
Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis 157
Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model 156
Unmet needs in outcome measures of Psoriatic Arthritis: focus on axial radiographic and nail involvement 156
Simple clinical indicators for early psoriatic arthritis detection. 156
Pharmacoeconomic issues in psoriatic arthritis 155
Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up 155
The arthritis of ulcerative colitis: clinical and genetic aspects 154
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients 154
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 153
Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study 153
Assessment of widespread and extra-articular pain in psoriatic arthritis: a case-control study 153
Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? 152
Somatic perception in irritable bowel syndrome (IBS) patients with and without fibromyalgia (FMS). Does the severity of IBS influence the perception of somatic stimuli? 151
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study 150
Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? 150
Assessment of Patient-Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study 146
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? 146
Patient education in psoriatic arthritis: a cross sectional study on knowledge by a validated self-administered questionnaire 146
Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions 145
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study 145
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy 145
Mesenchimal stem cells: A possible role in the pathogenesis and treatment of spondyloarthritis 144
The performance of CASPAR criteria in early psoriatic arthritis - preliminary results from an Italian prospective multicentric study 143
An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain 142
The role of IL-17 in the treatment of psoriatic arthritis 141
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. 140
Consensus on the management of patients with psoriatic arthritis in a dermatology setting 140
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations 139
Psoriatic arthritis: imaging techniques 138
Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation 138
Fibromyalgia is strongly associated with the severity of inflammatory bowel syndrome. 138
Venous thrombophilia with severe mesenteric involvement associated to homozygosity for factor V Leiden and heterozygosity for G20210A mutation of prothrombin 138
Validity of the modified stoke ankylosing spondylitis spine score (M-SASSS) and of the bath ankylosing spondylitis radiology index (BASRI) for the radiological assessment of axial involvement in psoriatic arthritis. multicentre validation study. Part one. 138
Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study 138
Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis 138
The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire 137
Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort 137
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 136
Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies 136
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. 135
The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. 135
Unmet Needs in Axial Spondyloarthritis 135
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study 134
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept 134
An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis 133
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs 133
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 133
Updated guidelines for the management of axial disease in psoriatic arthritis 133
New insights in occult psoriatic arthritis 133
Constrictive Pericarditis With Massive Calcification in Systemic Sclerosis Treated With Pericardiectomy: A Case Report 132
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis 132
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis. 132
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology 132
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. 131
Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study 131
Physical trauma triggers psoriasis in a patient with undifferentiated seronegative spondyloarthropathy 130
Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. 130
Multimorbidity and comorbidity in psoriatic arthritis–a perspective 130
Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study 129
Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? 129
Role of comorbidities in spondyloarthritis including psoriatic arthritis 129
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study 129
Trauma and seronegative spondylarthropathy 128
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review 128
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review. 128
LA COMPLICANZA ARTICOLARE DELLA MALATTIA CELIACA. STUDIO SU 62 CASI: RISULTATI PRELIMINARI 128
Difficult-to-treat concept in Psoriatic Arthritis: analysis of two potential definitions in a large group of patients. A cross-sectional study 128
The effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria 127
Totale 17.967
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022917 0 252 16 31 55 28 29 106 141 154 43 62
2022/20234.662 535 121 102 392 245 377 16 220 2.328 146 82 98
2023/2024855 238 133 55 21 30 72 18 47 19 47 84 91
2024/20253.476 460 120 432 92 544 143 60 258 306 114 431 516
2025/202617.071 455 1.664 3.317 926 3.192 2.686 1.600 581 596 1.424 385 245
2026/2027555 467 88 0 0 0 0 0 0 0 0 0 0
Totale 32.805